NCT03093116 2026-05-27TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 2 FDA
NCT06128551 2026-04-23Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1/2 Recruiting534 enrolled